naptumomab estafenatox

Ligand id: 9948

Name: naptumomab estafenatox

Compound class Antibody
ABR-217620 | ABR217620 | Anyara (proposed trade name) | TTS CD3 | TTS-CD3
Naptumomab estafenatox (ABR-217620) is an immuno-oncology clinical candidate biologic drug that is being developed by Active Biotech and NeoTX Therapeutics. It is a fusion protein containing a 5T4 (tumor-associated oncofetal trophoblast glycoprotein antigen) Fab moiety fused via the C terminus of the heavy chain to an engineered hybrid of Staphylococcus entertoxins A and E (SEA/E-120) superantigens [1]. Staphylococcal superantigens are secreted by the pathogen and stimulate a massive MHC class II-T cell receptor-mediated polyclonal T cell activation, which results in the release of large amounts of cytotoxic and proinflammatory cytokines and potent T-cell-mediated killing of tumour cells. Naptumomab estafenatox targets the destructive power of SEA/E-120 to 5T4-expressing tumour cells. The SEA/E-120 moiety is engineered to reduce MHC class II binding affinity so as to reduce killing of bystander MHC class II positive cells.
Database Links
Specialist databases
IMGT/mAb-DB 65
Other databases
ChEMBL Ligand CHEMBL1743045
GtoPdb PubChem SID 374883835